Generalized Anxiety Disorder | Treatment Algorithms: Claims Data Analysis | US | 2023
The use of pharmacotherapies for the treatment of generalized anxiety disorder (GAD) has grown sharply, fueled by an increasing prevalence of the disorder and constrained access to nonpharmacologic options. The GAD market is highly genericized, and the first lines of therapy (SSRI and SNRI antidepressants) are well tolerated, effective against anxiety and comorbid depression, and affordable. Nevertheless, only 60-85% of patients respond to current agents, only half of whom achieve remission; thus, patients must often resort to adjunctive therapy or progress to alternate therapies. Therefore, despite the genericization of early lines of therapy, brands emerge rapidly in subsequent lines of treatment for GAD and opportunities persist for more-effective anxiolytics, particularly with a faster onset of action than the current first lines of treatment. This report is critical for developers to appreciate the potential of novel therapies entering this market, the rate at which newly diagnosed patients progress to branded therapies, and the degree of spillover use of multiple therapies as PCPs and psychiatrists attempt to treat GAD and its comorbidities.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed GAD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed GAD patients?
- How has Takeda / Lundbeck’s Trintellix been integrated into the treatment algorithm, and what is its source of business?
- What percentage of GAD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of GAD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AbbVie, Lundbeck, Otsuka Pharmaceuticals, Takeda Pharmaceuticals, Sumitomo Dainippon Pharma / Sunovion, Intra-Cellular Therapies
Key drugs: Rexulti, Trintellix, Latuda, Savella, Fetzima, Vraylar, Viibryd, Fanapt, Caplyta
SOLUTION ENHANCEMENT
The Treatment Algorithms dashboard is an interactive supplement to our PowerPoint-based claims data analysis reports and retains the full set of analyses included in the reports (i.e., newly diagnosed patients, recently treated patients, persistency, and compliance). The dashboard allows for easier navigation of data visualizations and provides more detailed analyses examining the flow of treatment regimens in newly diagnosed and recently treated patients.
